Remicade infliximab regulatory update

Mitsubishi Tanabe said Japan approved Remicade infliximab to treat entero-, neuro- and vasculo-Behcet’s disease. Mitsubishi Tanabe markets the chimeric mAb against tumor necrosis factor (TNF) alpha i...